raised its full-year profit forecast on Wednesday on strong demand for its common respiratory vaccine and specialty HIV medicines, though it expects sales growth to slow in the second half.
Sales of recently launched products such as respiratory syncytial virus vaccine Arexvy and bone marrow cancer therapy Ojjaara have been strong since the start of 2024, while asthma drug Trelegy also performed better than expected, GSK said. GSK shares have risen more than 25% since the launch of its RSV vaccine in the U.S. in mid-August 2023. The FTSE 100 group's shares were up 1.8% to 1,703 pence by 0950 GMT.
RULES:RESULTS RHPI:PUBLIC-HEALTH MTPIX BACT BIZ BLR CMPNY COVID GEN GENHLT HEA HECA HUMDIS INFDIS NEWS1 PHAG08 PHAR PHAR08 PHAR1 PHMR PUBL PXP RES RESF VACCIN GB WEU EUROP EMEA FIN TOPNWS TOPCMB HOT STX
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: wsfa12news - 🏆 338. / 59 Read more »
Source: screenrant - 🏆 7. / 94 Read more »
GSK raises full-year profit forecastGSK raises full-year profit forecast
Source: Investingcom - 🏆 450. / 53 Read more »
Source: screenrant - 🏆 7. / 94 Read more »
Source: screenrant - 🏆 7. / 94 Read more »
Source: dallasnews - 🏆 18. / 71 Read more »